background
respiratori
virus
detect
larg
proport
adult
hospitalis
acut
respiratori
ill
influenza
virus
evid
viral
load
persist
associ
certain
clinic
outcom
known
associ
viral
load
hospit
length
stay
method
adult
hospitalis
viral
acut
respiratori
ill
studi
associ
viral
load
length
stay
examin
multipl
linear
regress
analysi
perform
control
age
comorbid
influenza
vaccin
statu
durat
ill
prior
hospitalis
bacteri
coinfect
clinic
group
viru
subtyp
result
high
viral
load
associ
longer
durat
hospitalis
patient
p
remain
signific
across
viru
type
clinic
group
adjust
age
comorbid
durat
ill
prior
hospitalis
bacteri
coinfect
factor
conclus
high
viral
load
associ
prolong
hospit
length
stay
adult
viral
acut
respiratori
ill
support
exist
evid
demonstr
viral
acut
respiratori
ill
viral
load
driven
process
suggest
viral
load
could
use
clinic
practis
predict
prolong
hospitalis
prioritis
antivir
intern
standard
randomis
control
trial
number
isrctn
viral
load
strongli
associ
length
stay
adult
hospitalis
viral
acut
respiratori
ill
introduct
acut
respiratori
tract
infect
respons
huge
burden
diseas
third
common
caus
death
worldwid
although
bacteria
previous
consid
princip
aetiolog
agent
sever
respiratori
infect
global
import
respiratori
virus
group
increasingli
recognis
recent
year
around
hospit
admiss
acut
respiratori
infect
england
exclud
exacerb
chronic
lung
diseas
recent
studi
shown
respiratori
virus
detect
around
hospitalis
adult
acut
respiratori
ill
influenza
viru
human
challeng
model
demonstr
viral
load
measur
viral
cultur
polymeras
chain
reaction
pcr
upper
respiratori
tract
sampl
correl
symptom
sever
magnitud
host
inflammatori
respons
hospitalis
adult
sever
complic
season
influenza
viral
load
highest
point
hospitalis
higher
protract
shed
compar
outpati
addit
time
viral
clearanc
relat
certain
clinic
outcom
group
includ
length
hospit
stay
hospitalis
patient
virul
avian
influenza
gener
life
threaten
diseas
pharyng
viral
load
admiss
hospit
higher
patient
season
influenza
higher
nonsurvivor
versu
surviv
respiratori
virus
also
data
adult
suggest
relationship
viral
load
clinic
outcom
human
challeng
model
use
healthi
adult
volunt
rsv
nasal
viral
load
close
correl
clinic
symptom
recoveri
observ
studi
shown
rsv
viral
load
higher
viral
shed
protract
hospitalis
adult
compar
outpati
high
viral
load
hospitalis
adult
risk
factor
develop
complic
includ
respiratori
failur
need
mechan
ventil
human
challeng
model
asthma
copd
exacerb
use
challeng
rhinoviru
viral
load
measur
sputum
correl
degre
host
inflammatori
respons
addit
studi
involv
healthi
univers
student
natur
acquir
rhinoviru
infect
demonstr
lower
viral
load
individu
asymptomat
rhinoviru
detect
compar
individu
symptomat
cold
appropri
endpoint
clinic
trial
respiratori
viru
antivir
hospitalis
adult
agre
antivir
drug
work
inhibit
viral
replic
avail
evid
suggest
virolog
clinic
outcom
close
correl
virolog
endpoint
suggest
use
primari
outcom
measur
antivir
trial
addit
studi
characteris
detail
relationship
clinic
virolog
outcom
hospitalis
adult
therefor
requir
clinic
outcom
measur
admiss
intens
care
unit
icu
death
rel
rare
outcom
adult
hospitalis
acut
respiratori
ill
sever
score
tool
predict
icu
admiss
death
proven
use
hospitalis
adult
influenza
potenti
outcom
measur
time
clinic
stabil
symptom
score
influenza
ill
unreli
potenti
flaw
popul
especi
elderli
may
display
typic
clinic
featur
may
also
cognit
impair
length
hospit
stay
key
determin
cost
patient
hospitalis
acut
respiratori
ill
repres
outcom
measur
clinic
econom
import
reason
often
employ
primari
secondari
outcom
measur
clinic
trial
hospitalis
patient
although
affect
factor
acut
ill
patient
age
comorbid
variat
practic
differ
centr
provid
adequ
control
hospit
length
stay
repres
use
robust
clinic
outcom
measur
suggest
prolong
hospitalis
eg
day
could
use
clinic
endpoint
futur
trial
influenza
antivir
addit
rarer
clinic
event
icu
admiss
death
defin
relationship
viral
load
length
hospit
stay
therefor
signific
interest
import
aim
studi
examin
associ
viral
load
measur
realtim
pcr
cycl
threshold
ct
valu
upper
respiratori
tract
sampl
point
admiss
hospit
length
stay
larg
cohort
adult
hospitalis
confirm
viral
acut
respiratori
ill
associ
high
viral
load
prolong
length
stay
would
support
exist
evid
suggest
viral
acut
respiratori
ill
viral
load
driven
process
could
use
clinic
identifi
patient
risk
prolong
hospitalis
stratif
particip
clinic
trial
candid
antivir
agent
cohort
studi
use
patient
recruit
part
prospect
trial
rapid
diagnost
test
influenza
streptococcu
pneumonia
studi
approv
leicestershir
northamptonshir
rutland
ethic
committe
prior
commenc
studi
patient
gave
written
inform
consent
patient
adult
hospitalis
acut
respiratori
ill
identifi
discharg
intern
classif
diseas
tenth
edit
code
classif
confirm
case
note
review
subject
particip
larg
prospect
studi
rapid
near
patient
test
pneumonia
influenza
met
follow
inclus
criteria
adult
age
year
age
abl
will
give
written
inform
consent
rel
carer
abl
will
give
inform
assent
acut
exacerb
chronic
respiratori
diseas
new
onset
acut
respiratori
ill
less
day
durat
abl
recruit
within
h
hospit
admiss
patient
recruit
winter
month
across
two
hospit
site
acut
medic
admiss
unit
within
univers
hospit
leicest
nh
trust
uk
patient
test
respiratori
viru
infect
detail
test
posit
respiratori
virus
viral
load
data
avail
includ
studi
patient
dual
viral
detect
exclud
fig
show
trial
profil
studi
demograph
clinic
data
present
symptom
sign
comorbid
medic
use
prior
antibiot
use
smoke
histori
vaccin
statu
collect
enrol
outcom
data
durat
hospitalis
measur
day
follow
admiss
admiss
high
depend
intens
care
unit
inhospit
mortal
day
mortal
collect
retrospect
record
standardis
case
report
form
radiolog
laboratori
data
collat
retrospect
use
computeris
imag
laboratori
system
patient
chest
radiograph
perform
within
h
admiss
radiograph
report
consult
radiologist
independ
studi
team
full
detail
clinic
group
definit
describ
previous
sampl
blood
urin
sputum
nasopharyng
swab
sampl
collect
enrol
nasopharyng
swab
sampl
collect
train
research
staff
accord
standard
protocol
swab
store
viral
transport
medium
frozen
c
prior
test
definit
viral
bacteri
infect
diagnost
method
bacteria
describ
previous
briefli
viral
nucleic
acid
extract
use
xtractorgen
nucleic
acid
extract
procedur
corbett
life
scienc
sydney
australia
accord
manufactur
instruct
start
volum
ml
use
elut
ml
viral
rnadna
ml
eluat
use
pcr
reaction
ml
final
reaction
volum
four
quadriplex
realtim
taqman
pcr
assay
employ
detect
follow
respiratori
virus
influenza
b
respiratori
syncyti
viru
rsv
b
parainfluenza
piv
type
adenoviru
enteroviru
rhinoviru
human
metapneumoviru
hmpv
group
coronavirus
group
coronavirus
sar
associ
coronaviru
full
detail
pcr
method
includ
primer
probe
sequenc
control
cycl
condit
previous
describ
respiratori
viru
test
perform
staff
use
rotorgen
pcr
machin
corbett
life
scienc
sydney
australia
standard
laboratori
protocol
laboratori
staff
blind
clinic
data
realtim
pcr
cycl
threshold
ct
valu
repres
first
pcr
cycl
fluoresc
signal
target
ie
viral
rna
greater
minim
detect
level
ct
valu
invers
proport
quantiti
target
offer
semiquantit
assess
viral
load
low
ct
valu
repres
high
viral
load
vice
versa
statist
analysi
perform
independ
statistician
use
prism
version
graphpad
softwar
la
jolla
ca
stata
statacorp
baselin
characterist
present
use
appropri
summari
measur
initi
ct
valu
viral
load
categoris
group
kruskalew
test
use
explor
differ
baselin
characterist
across
group
primari
analysi
zerotrunc
neg
binomi
regress
use
assess
associ
outcom
variabl
durat
hospitalis
measur
day
ct
valu
viral
load
multivari
model
control
age
sex
comorbid
influenza
vaccin
statu
durat
ill
prior
hospitalis
presenc
bacteria
clinic
group
exacerb
asthma
exacerb
copd
commun
acquir
pneumonia
influenzalik
illnessbronch
viru
subtyp
influenza
b
rhinoenteroviru
virus
covari
identifi
priori
zerotrunc
model
chosen
due
fact
durat
hospitalis
could
less
one
day
neg
binomi
regress
chosen
due
overdispers
outcom
suggest
poisson
regress
appropri
tabl
age
hospit
length
stay
associ
ct
valu
ie
high
viral
load
p
z
p
respect
patient
combin
ct
valu
invers
correl
hospit
length
stay
ie
length
stay
increas
ct
valu
decreas
viral
load
increas
r
z
ci
p
z
spearman
rank
correl
length
stay
longer
patient
ct
high
viral
load
patient
combin
p
patient
influenza
p
z
rhinoenteroviru
p
z
virus
p
z
also
clinic
group
pneumonia
p
z
exacerb
asthma
p
z
exacerb
copd
p
z
ili
bronchiti
p
z
examin
individu
clinic
group
viru
subtyp
associ
hospit
length
stay
ct
valu
viral
load
strongest
influenza
patient
exacerb
copd
p
z
pneumonia
p
z
rhinoenteroviru
patient
asthma
exacerb
p
z
although
small
number
patient
infect
certain
viral
subtyp
clinic
group
meant
meaning
comparison
possibl
subgroup
tabl
fig
examin
marker
sever
patient
pneumonia
score
higher
patient
influenza
ct
high
viral
load
p
z
patient
virus
detect
shown
supplementari
appendix
tabl
fig
demonstr
kaplanemei
surviv
curv
hospit
length
stay
ct
valu
viral
load
patient
combin
multipl
logist
regress
analysi
demonstr
ct
valu
viral
load
associ
hospit
length
stay
independ
age
sex
comorbid
influenza
vaccin
statu
durat
ill
prior
hospitalis
bacteri
coinfect
clinic
group
viru
subtyp
p
everi
unit
decreas
ct
valu
ie
increas
viral
load
increas
hospit
length
stay
age
comorbid
respiratori
diseas
bacteri
infect
clinic
group
also
independ
associ
durat
hospitalis
tabl
larg
cohort
studi
adult
hospitalis
viral
acut
respiratori
ill
demonstr
viral
load
measur
nasopharyng
sampl
point
admiss
hospit
associ
hospit
length
stay
high
viral
load
strongli
associ
longer
durat
hospitalis
consist
find
across
clinic
group
viru
subtyp
maintain
adjust
age
comorbid
durat
ill
bacteri
coinfect
potenti
confound
factor
result
support
exist
bodi
evid
suggest
respiratori
virus
may
caus
sever
acut
respiratori
ill
result
clinic
ill
viral
load
driven
process
clinic
outcom
predict
viral
load
magnitud
kinet
persist
whilst
alreadi
substanti
bodi
evid
suggest
relationship
certain
clinic
outcom
viral
load
influenza
respiratori
virus
first
studi
demonstr
associ
viral
load
hospit
length
stay
show
relationship
multipl
clinic
group
across
multipl
viral
subtyp
within
studi
find
suggest
detect
high
nasopharyng
viral
load
adult
patient
hospitalis
acut
respiratori
ill
could
use
clinic
identifi
patient
high
risk
prolong
hospitalis
although
current
laboratori
test
influenza
use
realtim
pcr
gener
ct
valu
routin
gener
avail
clinician
use
clinic
decis
make
studi
suggest
result
could
pass
clinician
use
inform
clinic
decis
make
includ
prioriti
use
neuraminidas
inhibitor
influenza
antivir
virus
becom
avail
median
durat
ill
prior
hospitalis
day
interquartil
rang
day
cohort
detect
associ
durat
ill
prior
hospitalis
viral
load
present
suggest
contrast
healthi
adult
uncompl
viral
infect
viral
load
peak
quickli
declin
rapidli
hospitalis
adult
complic
respiratori
viral
ill
viral
load
remain
import
determin
clinic
outcom
later
time
point
therefor
potenti
modifi
effect
antivir
therapi
consist
number
observ
studi
hospitalis
adult
influenza
show
reduct
viral
load
clinic
benefit
neuraminidas
inhibitor
even
start
beyond
h
symptom
durat
although
explor
studi
high
viral
load
also
suggest
increas
infecti
increas
risk
nosocomi
spread
patient
high
viral
load
detect
admiss
hospit
would
repres
prioriti
group
side
room
isol
enhanc
infect
control
practic
respiratori
viru
nasopharyng
viral
load
use
primari
endpoint
clinic
trial
novel
antivir
basi
associ
viral
load
clinic
symptom
outcom
studi
strengthen
posit
extend
patient
respiratori
virus
rhinoviru
patient
specif
less
well
studi
clinic
group
exacerb
asthma
copd
furthermor
studi
suggest
high
viral
load
could
use
method
stratifi
patient
futur
trial
novel
candid
antivir
agent
durat
hospitalis
use
outcom
measur
strength
studi
includ
larg
number
patient
confirm
viral
acut
respiratori
ill
consist
pcr
method
patient
use
multipl
logist
regress
analysi
adjust
confound
variabl
age
comorbid
durat
ill
prior
hospitalis
bacteri
coinfect
addit
patient
influenza
treat
neuraminidas
inhibitor
cohort
consist
uk
prescrib
practic
time
studi
prior
influenza
pandem
allow
uniqu
opportun
examin
associ
viral
load
clinic
outcom
untreat
patient
influenza
without
confound
antivir
treatment
although
larg
real
world
clinic
studi
generaliz
typic
adult
patient
hospitalis
acut
respiratori
ill
sever
limit
retrospect
observ
studi
prone
bia
although
well
control
use
multivari
model
includ
variabl
known
potenti
influenc
hospit
length
stay
exclud
possibl
unpredict
unmeasur
variabl
influenc
result
find
studi
howev
biolog
plausibl
consist
previous
publish
studi
demonstr
relationship
viral
load
clinic
outcom
furthermor
associ
seen
studi
high
viral
load
increas
sever
influenza
pneumonia
use
score
suggest
high
viral
load
inde
marker
sever
patient
hospitalis
acut
viral
respiratori
ill
use
formal
quantit
pcr
qpcr
assay
studi
instead
reli
semiquantit
ct
valu
realtim
pcr
assay
realtim
pcr
ct
valu
consid
mani
robust
surrog
quantifi
viral
load
increasingli
report
publish
studi
acut
viral
ill
includ
examin
respiratori
virus
also
recent
ebola
viru
pandem
furthermor
use
protocolis
sampl
techniqu
process
dedic
research
staff
remov
interoper
variabl
result
interpret
sampl
analys
scientist
laboratori
give
reassur
robust
ct
result
studi
although
patient
respiratori
swab
taken
nasopharynx
standard
clinic
practis
test
respiratori
virus
uk
site
may
insensit
detect
respiratori
virus
patient
lower
respiratori
tract
infect
studi
found
increas
rate
respiratori
viru
detect
sputum
compar
upper
respiratori
tract
sampl
possibl
patient
exclud
due
neg
pcr
nasopharyng
sampl
may
actual
detect
virus
lower
respiratori
tract
also
possibl
virus
detect
upper
lower
respiratori
sampl
viral
load
might
differ
two
would
suggest
find
studi
valid
larg
prospect
cohort
incorpor
sampl
upper
lower
respiratori
tract
examin
viral
kinet
persist
cours
hospitalis
summari
studi
demonstr
high
viral
load
measur
nasopharyng
sampl
point
hospitalis
associ
longer
length
stay
adult
patient
viral
acut
respiratori
ill
viru
subtyp
across
clinic
group
confirm
studi
could
use
clinic
practic
identifi
patient
risk
prolong
hospit
stay
prioritis
antivir
treatment
enhanc
infect
control
practis
